Since atRA enhanced, and the pan-RAR antagonist AGN193109 decreased, key LSCe/LSC properties in an Evi1 dependent manner ex vivo, we next asked whether AGN193109 would inhibit leukemia formation and stemness in vivo. Here, RUNX1 is linked to leukemia.